Despite a net loss, Moderna Inc (MRNA) showcases resilience with significant cost cuts, new FDA approvals, and a robust cash ...

Moderna is counting on new mRNA products such as its experimental COVID-flu combo shot to offset slumping COVID vaccine sales ...

Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, ...

HHS Secretary Robert F. Kennedy Jr. has upended the way Covid vaccines are approved and for whom they’re recommended, ...

US pharmaceutical giant Pfizer and German firm BioNTech lost Friday a court appeal in the latest step of a multi-million-pound battle against US rival Moderna over the Covid-19 vaccine.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Discover the latest Wall Street trends: market declines, Q2 earnings highlights, and key stock moves from Tesla, Meta, Microsoft, and more.

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

The emerging technology promises better medicine, faster internet and more sustainable food production. It also comes with ...

Exxon Mobil CEO Darren Woods said the oil giant is looking for acquisition opportunities in the oil-and-gas space after losing its challenge to Chevron's $53 billion deal to buy Hess. Wal-Mart de ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Stocks fell sharply Friday as investors responded to President Donald Trump's latest moves on tariffs and an employment ...